IMPACT REPORT 2023

OXFORD'S IMPACT ODYSSEY

Embracing Impact: The road to becoming a science superpower

IMPACT REPORT 2023
OXFORD'S IMPACT ODYSSEY

CONTENTS

Embracing Impact:
The road to becoming
a science superpower

If we want to have any hope of meeting the great challenges of our age – climate change, global health, inequalities, digital transformation – we must deploy and scale scientific and technological innovation at greater intensity than ever before.

In Oxford, we understand this. Our response is translating our world-leading academic research into commercial, scalable innovations that have the capacity to respond to complex societal problems. The Oxford-AstraZeneca Vaccine deployed during an unprecedented pandemic is evidence of this.

"**OUI** is a catalyst for taking academic research beyond study and laboratory walls and into the outside world, driving both societal and economic impact."

In this – our first impact report – we set out our ability to push the boundaries of science, technology and social enterprise through company creation and through negotiating consulting partnerships with industry, government and beyond. Next year we plan to begin reviewing the impact of our licensing portfolio. Further metrics are in development as we seek to refine our approach to measuring impact.

As the technology transfer company of the University of Oxford, OUI provides support and expertise to enable researchers to harness commercial opportunities and begin their journey to deliver economic and societal impact. Epitomised by spinouts and startups such as Vaccitech, Mind Foundry, OrganOx and Wise Responder – you'll discover just a few of our cutting-edge companies.

Baroness Nicola Blackwood,
Chair of Oxford University Innovation

Photo by UK Parliament

"At OUI we are fully aligned with both the UK intention to invest **2.4% of GDP in Research & Development** by 2027, with **£370 million** for the UK's most promising emerging technologies, and the UN Sustainable Development Goals (SDGs)".

At OUI, we are fully aligned with both the UK intention to invest 2.4% of GDP in Research & Development by 2027, with £370 million for the UK's most promising emerging technologies, and the UN Sustainable Development Goals (SDGs).

Indeed, this report maps our companies' commitment to help deliver the SDGs and how we are able to support this through working closely with our partners across the University, the investor community and industry.

In Oxford, we are driving the UK's knowledge economy and helping to strengthen our nation's position on the global stage of science, technology and enterprise.

I hope you will join us in celebrating the achievements we report here. But if we want to have a hope of responding to the urgency of the great global challenges of today, we need to work together at pace and scale to develop new opportunities to deliver more impact today and for future generations. I look forward to working with you to do just that.

Oxford University Innovation: A conduit for impact

For more than 35 years, Oxford University Innovation (OUI) has helped researchers make an impact in the world. The word impact, though, has never meant as much – or as many different things – as it does today.

There's the immediate impact seen when an individual academic performs consultancy work to solve a problem for an external client – or when a University department provides use of its high-tech equipment. There's the social venture putting its profits towards tackling a global challenge; the promising medical invention licensed to a bigger company for onward application; the major biotech creating hundreds of regional jobs while it works long-term to treat or cure a disease.

Our Internal Impact 2022 / 23

£34m
Total Income

£15.9m
Returns to the University

333
Total Disclosures

66
New Patent Filings

20
New Companies

1
Incubator Startup

16
Spinouts

3
Social Ventures

81
Total Deals

Consulting Services

Clinical Outcomes

652
Contracts with **383** Individual (unique) Companies

853
Executed Agreements

Quick Facts

£34 million total income (2022 / 23)

£15.9 million returned to the University

853 Clinical Outcomes executed agreements

OUI facilitates research commercialisation and consulting partnerships. All of these companies, licensing and consulting agreements originate in Oxford's unique environment of interdisciplinary academic collaboration, and all of them are making the world a better place – in a multitude of different ways. Impact flows out from the University and any financial returns to the University flow back to further the mission of teaching and research, and fund and support the development of innovative, impactful ideas of the future.

When thinking about how to measure impact, OUI decided to use the United Nations Sustainable Development Goals as a framework to assess and report this activity. A survey of Oxford's spinout companies, startups and social ventures suggests that together they are contributing to almost all these 17 targets, from ending poverty and hunger to improving health, achieving gender equality, creating resilient infrastructure and combating climate change. We are very proud of this first impact report assessment and invite more of our companies and partners to participate next year.

As the number of companies created, patents filed, licences agreed and consultancies performed increases year on year, so too will the economic and societal impact generated by the University and its world-leading researchers.

The Oxford Opportunity

In 2023, the University of Oxford achieved a milestone with the creation of its 300th company, confirming Oxford's pole position as the UK's most prolific creator of university-originated companies.

Starting with Oxford Instruments in 1959, the University has created academic spinouts, social ventures and startups across the breadth and depth of its many scientific disciplines. Companies are providing grand solutions to global challenges, with Oxford DNA at their core.

Ideas born from Oxford's physics research are creating quantum computers and fusion energy. Our life science researchers are developing life-saving vaccines and finding solutions to treat the untreatable. Roboticists and computer science academics are putting autonomous vehicles on the road and building new models of AI.

Quick Facts

20 new companies

£698.8 million raised across portfolio companies

£32 million seed funding available

A science superpower

Pivotal to the UK's aspirations of establishing itself as a science superpower, Oxford delivered 20 new companies between 2022 / 2023, raising £32 million collectively at the seed round. Most notably, serial academic entrepreneur Professor Robert MacLaren co-founded Beacon Therapeutics, a life sciences company building on his work with Nightstar Therapeutics, raising £96 million in series A funding for its genetic therapeutics technology capable of curing rare diseases which cause blindness.

John Cairns Photography

Oxford's family

Our family of companies secured a further £698.8m in venture investment over the same period 2022 / 2023 – funding that will scale and accelerate transformative technologies for the benefit of our economy and our society.

Osler Diagnostics, a company realising the holy grail of fast and effective tabletop diagnosis equipment, capable of identifying a range of conditions from a single prick of blood, secured £71 million when it emerged from stealth. Meanwhile, Oxford's dynamic quantum community was bolstered by news of Quantum Motion, a company developing silicon-based quantum computers, raising £40 million.

This investment has been galvanised by the tremendous efforts of Oxford Sciences Enterprises (OSE). To date, OSE has invested £600 million into Oxford companies, significantly contributing to the £6.3 billion invested in Oxford companies since 2011. This direct investment has been met with co-investment from leading global investors and has catalysed our capacity to create ground-breaking companies. Since OSE's creation in 2015, over half of Oxford's 300 companies have been created, rising from an average company formation rate of 4 or 5 per year to 20 per annum.

Evolving the offer

In addition, Oxford has evolved our offer to our entrepreneurial student body. The University recently launched EnSpire, connecting up initiatives across the Saïd Business School, OUI's Incubator, Careers Services, the Creative Destruction Lab, and the wider Oxford ecosystem to bolster innovation from the next generation of startup leaders. This work recently received investment from OSE into the student-run Oxford Seed Fund to accelerate the innovative ideas of our student body.

"Together with the University, our companies, and our partners in the Oxford ecosystem, OUI is helping support **£3.4 billion** of **economic impact per annum**"*

Oxford University Innovation, the conduit for impact between the University and the outside world, has recorded another strong financial performance, returning £15.9 million to the University and our academic community. Consulting Services in particular continues to smash its own targets year on year, while also working hard to support agreements with industry to more readily use University labs and facilities.

A growing community

Together with the University, our companies, and our partners in the Oxford ecosystem, OUI is helping support £3.4 billion of economic impact per annum* with the combined research and innovation activity associated with the University supporting the creation of over 28,000 jobs.

To meet the needs of the rapid growth in Oxford's innovation community, the University formed a partnership with Legal and General to develop the infrastructure necessary to give these young firms a place to scale. This £4 billion project committed £300 million to shovels in the ground around the University's Begbroke Science Park – Phase 1 of a plan to transform the area into an Innovation District.

With multiple other developments in the pipeline, and job creation 140% higher than the national average, Bloomberg recently declared that "Oxford's star is now on the ascendant".

Despite the record growth of Oxford's innovation community, many still share the view that our story is just getting started. Oxford Nanopore's 2021 blockbuster IPO was a climactic moment for the DNA sequencing firm, but it was also a starting gun for the wider community, with many aspiring businesses vying for the same exponential growth and transformative impact from their companies.

This is our moment to realise the Oxford Opportunity. To secure its potential, we are reaching out to explore new partnership opportunities with the world's technology, science and business leaders, impact-driven investors and industry partners.

Work together with OUI and the world's number one University to make a better world and deliver impact tomorrow, and now and for future generations.

* Based on 2021 London Economics report *Economic Impact of the University of Oxford* for 2018 / 2019 period.

"Oxford University Innovation, the conduit for impact between the University and the outside world, has recorded another strong financial performance, returning **£15.9 million** to the University and its academic community."

OUI financial performance stats

OUI's income and expenditure year to 31 July 2023 (£'000)

Income:
- Licensing & Ventures: 16,025
- Clinical Outcomes: 1,061
- Management fee: 5,576
- Consulting Services: 8,786
- Equity Realisations: 1,136
- Other Income: 1,733

Expenditure:
- Profits returned to University: 15,947
- Operating costs: 8,592
- Investment: 5,514
- Profit before tax: 4,263

Our Impact Methodology

At OUI, we define "Impact" as a change in an outcome caused by an organisation. There can be economic, financial, social and environmental impact.

This report includes a section on OUI's impact on the University of Oxford's entrepreneurial ecosystem, which we call our "internal impact". The rest of the report focuses on the impact from new companies that we've helped to form and our consulting services, alongside some case study examples. This is the "**external impact**" which is delivered by companies that we have supported.

We have chosen to focus on companies primarily for this first report, alongside Consulting Services, and intend to expand our data capture to licensing activities in the coming years.

External impact data

58 Oxford companies reported to OUI on number of users, UN SDGs and impact metrics.

Across those **58 companies**

44 companies define impact metrics for their products / services.

21 companies currently capture impact data from current sales / activities.

52 companies address UN SDGs.

66,451,696 Users

1 NO POVERTY — **5** companies	2 ZERO HUNGER — **5** companies	3 GOOD HEALTH AND WELL-BEING — **32** companies
4 QUALITY EDUCATION — **11** companies	5 GENDER EQUALITY — **13** companies	6 CLEAN WATER AND SANITATION — **4** companies
7 AFFORDABLE AND CLEAN ENERGY — **7** companies	8 DECENT WORK AND ECONOMIC GROWTH — **18** companies	9 INDUSTRY, INNOVATION AND INFRASTRUCTURE — **17** companies
10 REDUCED INEQUALITIES — **13** companies	11 SUSTAINABLE CITIES AND COMMUNITIES — **6** companies	12 RESPONSIBLE CONSUMPTION AND PRODUCTION — **8** companies
13 CLIMATE ACTION — **11** companies	14 LIFE BELOW WATER — **3** companies	15 LIFE ON LAND — **8** companies
16 PEACE, JUSTICE AND STRONG INSTITUTIONS — **1** company	17 PARTNERSHIPS FOR THE GOALS — **7** companies	THE GLOBAL GOALS For Sustainable Development

Companies can address more than one UN SDG.
View UN SDG website to see the 17 goals in detail.

Measuring External Impact

We asked our companies to complete a questionnaire about the:

- Number of users,
- United Nations Sustainable Development Goals (UN SDGs) addressed,
- Impact metrics (up to three) that the company chooses to measure the outcomes of their products or services, and
- Any data relating to realised impact.

This report is a summary of the results of that survey plus analysis of themes and countries where consulting services create impact.

OUI has a large portfolio with very early-stage companies, so it is no surprise that not all companies are measuring their impact or that some with defined metrics don't yet have data to report. The types of impact are also diverse. We intend to support our companies over the coming years to better understand how they can effectively measure their outcomes and track their impact.

Companies and consultancies are predominantly engaged in four primary themes:

Health and Wellbeing	Social Equity & Education	Environment	Other sectors*
27 companies	**13** companies	**12** companies	**5** companies
425 consultancies	**48** consultancies	**28** consultancies	**73** consultancies

*Other includes materials, engineering, internet and AI not relating to the other categories.

**7.5 million** patients given a voice through our Clinical Outcome Assessments.

More than **3 billion** COVID-19 vaccine doses delivered to **180** countries by the end of 2022.

Up to an estimated **122.4 million** hospitalisations prevented.

6.3 million lives saved in first year of global vaccine rollout.

In 2022 / 23, **383 individual** companies used academic consultants or university facilities and equipment to drive the impact of their business **(652 contracts)**.

383 Companies were supported across **29** countries and **5** continents.

Map showing 29 countries where consultancies occur.

♥ Health and Wellbeing

TdeltaS

TdeltaS Ltd's unique ketone ester, deltaG®, increases physical performance, sharpens mental acuity, and supports metabolic health in over **10,000 customers**, including elite athletes and the military.

LiliumX

LiliumX has screened **over 150 modular compounds and over 10 drug candidates**. They have one partnered drug programme.

Brainomix

Brainomix's e-Stroke has processed over **1 million stroke scans to guide treatment decisions in over 350 hospitals**.

Refeyn

Refeyn has installed 250 mass photometry instruments which have facilitated **200 research papers**.

Ultromics

Ultromics' AI platform, EchoGo, for detecting heart failure with preserved ejection fraction (HFpEF) has been used in over **100,000 patients**. With a **90% accuracy rate, it enables 68% improved detection of HFpEF** with fewer indeterminates vs current clinical risk scores.

Oxford Nanopore

Oxford Nanopore **serves more than 43,000 community users across 120 countries enabling over 8800 publications** using nanopore technologies. Their impact spans biodiversity conservation, outbreaks and pandemics, disease characterisation and whole genome sequencing.

SERENOx

SERENOx has supported the creation of the first specialist clinic and laboratory for patients with blood diseases and cancer in Tanzania. Over **500 people have been tested to determine blood diseases and cancer**, enabling them to access life-saving treatment.

Social Equity and Education

Inkpath

Inkpath now has **52,500 users across 94 universities** and institutions. Approx 384,000 hours logged by users over time.

OxEd

OxEd has screened half a million children for language skills in England, identifying 100,000 as falling behind and providing the NELI programme to help them catch up. **Children demonstrated 3-5 months' additional progress in language skills in six months**, which was matched by children with English as a second language. Children's behaviour also significantly improved.

Greater Change

Greater Change has supported **722 people out of homelessness, with 84% of people housed and over 50% of people employed**. They have saved £21.2 million for local and central government.

HOW WE WORK

FOR PEOPLE WHO ARE HOMELESS

We work with brilliant partner charities, who refer clients like Steve to us. Together, Steve and his key worker decide what is most useful for Steve's move on.

Steve knows what his most urgent needs are because it's his direct experience. He tells Greater Change he needs a driving license and work tools, so he can get back into his trade.

Together they create a campaign on Greater Change, to help fund Steve's needs. Lots of different people donate directly to the campaign.

When the funds are raised the key worker and Steve procure the things he needs together.

GreaterChange

Collegia

Collegia's pensions exclude or minimise controversial industries and **actively finance companies aligned with the UN Sustainable Development Goals.** The company currently has thousands of members and employers enrolled into the platform.

Global Health Research Accelerator

The Global Health Research platform, supported by the Global Health Research Accelerator non-profit company has enabled thousands of new studies, with **450,000 researchers up-skilled in healthcare settings and 4.5 million online courses taken**.

ORBIT RRI

ORBIT RRI has provided training on Responsible Research and Innovation to **3000 PhD students in the UK and 204 students in developing countries** with the British Council. They provide training in 30 separate technology domains including AI, agriculture, biomedical science, chemistry and engineering.

Environment and other sectors

Environment

OxCarbon

OxCarbon's carbon credit projects have removed **207,424 metric tonnes of CO^2 through avoided emissions or removals in 2021 / 22**. Four villages in North Sumatra have been positively affected by projects. They are partnering with BeZero to give independent ratings to projects.

Other sectors

Diffblue

Diffblue's generative AI for code has saved users of their free product **370 years of low-value software development time** over three years across 3.2 million tests.

Covatic

Covatic's private-by-design, advertising without exposing personal data has been used by **60 million people** to date. In November 2021 the company became OUI's first portfolio certified B Corporation.

Nick Pinks
CEO

OUI Consulting Services: Creating instant impact

In the last year alone, OUI's Consulting Services team negotiated more than 650 contracts with clients spanning 29 countries across five continents.

That's more than 650 examples of immediate impact worldwide.

"Organisations come to us because they have a problem that Oxford academics can solve," says Jaci Barnett, Head of Consulting Services, OUI. "Those organisations reap the rewards quickly and directly, to the benefit of their business or project and its end users."

Consulting Services has two primary roles: to help industry harness the knowledge and expertise of Oxford academics, and to enable industry's use of the University's facilities and equipment. The team works across all Divisions of the University, facilitating projects to the benefit of the University and external organisations.

Examples of Consulting Services' management and guidance include:

- **Service contracts with the Department of Oncology.** Projects have included tissue sample processing for a spinout company developing new cancer drug delivery systems, and access to equipment such as high-specification microscopes for a large company developing cell and gene therapies for serious diseases including cystic fibrosis. The department has highlighted the significant benefits of OUI's support in developing and maintaining these important relationships with industry.

- Projects for consultants from the **Department of Computer Science** who perform assessments of a country's cybersecurity capacity maturity. Based on the Global Cyber Security Capacity Centre's internationally recognised Cybersecurity Capacity Maturity Model for Nations, the consultants undertake desktop studies and facilitate focus group discussions to produce detailed reports and recommendations for cybersecurity capacity building and investment. Consultancy projects have made an impact in countries including Switzerland, Cyprus, Bahamas, Cambodia, Haiti, Brazil and Libya.

- A range of specialist digitisation projects for the **Digital Image Archive of Medieval Music (DIAMM)**. DIAMM is part of the Faculty of Music but works not only in the field of musicology: manuscripts digitised include the Exon Domesday book, the Winchester Bible, and Eton College Dante manuscripts. The project creates high-quality, colour-accurate digital surrogates, providing free access to cultural heritage objects for the academic community and the wider public, while protecting them from damage and preserving them for future generations.

John Cairns Photography

- More than 20 consultancy projects carried out by **Rob McNeil of Oxford's Migration Observatory** within the **Centre on Migration**, Policy and Society (COMPAS). From summer schools to handbooks, Rob's work with journalists and communicators across Europe helps shape and enhance the quality of public debate around migration, as well as returning knowledge and benefits to his day-to-day work at the University.

The projects – whether personal consultancy, services or access to equipment – create instant impact for external organisations, allowing them to develop, adapt and grow.

"Organisations come to **Consulting Services** because they have a problem that **Oxford** academics can solve."

Quick Facts

Consultancy projects have made an **impact** in countries including **Haiti, Brazi**l and **Libya**

DIAMM provides access to **cultural heritage** objects preserving them for **future generations**

Mind Foundry: AI for high-stakes applications

In the era of big data, the ability to extract meaningful insights from vast amounts of information is paramount. However, the complexity of AI and machine learning has largely confined its use to specialists – and its reputation for ethics and transparency is often in discussion.

Mind Foundry breaks these barriers with a Responsible AI Platform that empowers organisations to create, implement and monitor their AI models at scale. Founded in 2016 by world-leading Oxford scientists Professor Michael Osborne and Professor Stephen Roberts – two experts synonymous with the field of machine learning – Mind Foundry's mission is to create a future where humans and AI work together to solve the world's most important problems.

> **"Mind Foundry's** stated mission is to **increase access to AI that can radically transform our world for good**."

Quick Facts

286 end users

Increased detection of fraudulent claims at major insurance company AND-E by **120%**

Increased referrals retained by AND-E's insurance fraud department by **800%**

Saved 2% on AND-E's capped indemnity spend in 2022 - tracking to double that in 2023

In its short history, Mind Foundry's AI has:

- Analysed sound recordings of mosquitoes buzzing to track the movement of malaria-carrying species – and save lives.
- Accelerated quantum computer calibration with an intelligent algorithm that resulted in a 100x speed increase.
- Helped a large retail bank to analyse free-text form entries, saving time and money.
- Optimised the design of experiments in the chemical processing industry, maximising the quantity of chemicals produced and minimising costs.
- Monitored complex in-flight propulsion systems by enabling the compression of data and solving a company's bandwidth bottleneck.
- Developed tools to help clients assess the carbon impact of their own AI models.

Mind Foundry's technology has been particularly beneficial for the insurance, public, and defence and security sectors. A partnership with the Scottish government on data-driven decision-making, has informed the country's national AI strategy. In the insurance sector, Mind Foundry has helped companies stay one step ahead of fraudulent claimants and better understand risk throughout their portfolio.

It's a long list of successes that will – like our use of AI and machine learning – only keep on growing at pace.

mind FOUNDRY

Case Study

Vaccitech and the Oxford-AZ COVID-19 Vaccine: Spearheading global health innovation

A landmark partnership between academia and industry. A commitment to equity and fair access. A vaccine developed in under a year. An estimated 6 million lives saved globally in 2021 alone.

The amazing and well-known story of the Oxford-AstraZeneca COVID-19 vaccine and its protagonists is the story of one of the most significant health breakthroughs in recent history.

The vaccine was co-developed by Oxford spinout Vaccitech and the University's Jenner Institute (where Vaccitech has its academic origins through co-founders Professor Sarah Gilbert and Professor Adrian Hill).

Vaccitech's ChAdOx platform uses a replication deficient chimpanzee version of the common cold virus as a vector for the key ingredient – in COVID's case the genetic material of the SARS-CoV-2 spike protein – that primes the recipient's immune system to fight off an infection if or when it arrives.

While best known for its role in the battle against COVID, Vaccitech's technology can also be turned towards a host of other diseases and disease areas, harnessing the power of the immune system's T cells.

With Vaccitech's proven scientific expertise and a broad, high-value portfolio, the company listed on the NASDAQ stock exchange in 2021 and acquired Avidea Technologies at the beginning of 2022. The Avidea acquisition added the SNAPvax™ platform to Vaccitech's portfolio; a self-assembling, fully synthetic platform that co-delivers multiple antigens and immunomodulators, and gives the company opportunities to advance into the autoimmune space.

Vaccitech's current pipeline includes novel T cell immunotherapeutics, at various stages of development, for hepatitis B, HPV, coeliac disease, prostate cancer and MERS. Beyond Vaccitech itself, researchers at universities worldwide are using its proprietary technologies to develop vaccines for deadly and debilitating viruses such as rabies, malaria, HIV and Zika (to name just a few).

The societal and economic impacts of Vaccitech and the Oxford-AZ vaccine are extraordinary. Beyond the immediate benefits of reducing COVID-19's spread and severity, the vaccine has helped revive economies, reopen societies, and restore a sense of safety and normality to billions of citizens worldwide.

"**Vaccitech's** current pipeline includes novel T cell immunotherapeutics, at various stages of development, for hepatitis B, HPV, coeliac disease, prostate cancer and MERS."

Quick Facts

COVID-19 vaccine: more than **3 billion doses** delivered to **180 countries** by end of 2022

COVID-19 vaccine: up to an estimated **122.4 million hospitalisations prevented**

9 programmes in Vaccitech's pipeline across infectious diseases, cancer and autoimmunity

The Oxford Knee Score: Innovating patient-centric healthcare assessments

Before the Oxford Knee Score (OKS), the assessment of a patient's progress after knee replacement surgery was based largely on the judgement of the doctor. The OKS changed that, giving patients a voice and ensuring that their experiences and insights help shape decisions about their treatment.

Developed by medical scientists at Oxford University in the late 1990s, the OKS has gone on to become a globally renowned exemplar of patient-centred outcome reporting, transforming orthopaedic care along the way.

Quick Facts

12-item questionnaire

25 years in clinical use

Oxford Knee Score and Oxford Hip Score used to assess **120,000** operations in NHS hospitals each year

The simple, yet comprehensive, 12-item OKS questionnaire asks knee replacement patients to rate, on a five-point scale, their levels of functionality and pain following surgery. Score under 20 and it may be an indication of severe arthritis; score 40 or more and things are looking good.

The societal and economic impacts of the OKS are substantial: by enabling more effective treatment strategies and facilitating the assessment of health interventions, it has not only improved patient quality of life but enabled the optimisation of healthcare resources and the identification of high-performing providers.

Although originally developed to evaluate total knee replacement, the OKS has broadened its scope for use in other joint disorders and treatments (for example, the Oxford Hip Score). It has enhanced patient-doctor communication, reduced the influence of bias, and improved both the management of joint conditions and the evaluation of treatment outcomes.

Today, the OKS is widely used in clinical practice and research globally, thanks to being made available for licence and translation by Oxford University Innovation. It has become a standard tool for assessing the effectiveness of various knee treatments, including surgery, rehabilitation, and medication.

The Oxford Knee Score stands as testament to the profound impact of Oxford University's patient-centric innovation activities – over not just years, but decades.

"The OKS has gone on to become a globally renowned exemplar of patient-centred outcome reporting, transforming orthopaedic care along the way."

OXFORD
Knee Score
(OKS)

Wise Responder: Empowering companies to tackle poverty

For over a decade, the Oxford Poverty and Human Development Initiative (OPHI) has developed tools to measure 'multidimensional' poverty. These tools provide a more comprehensive picture of poverty, showing not only the scale of poverty in a region, but also what type of deprivations those in poverty experience (for example, lack of sanitation or lack of access to healthcare services).

Out of that award-winning work came Wise Responder – the University of Oxford's very first social venture. Wise Responder provides social metrics for financial institutions, investors, companies and governments to help them tackle the world's number one sustainable development goal: ending poverty.

It does this through two key products:

- The Poverty Zero Index, which gives licensed users the ability to access never-before-available, regularly updated scientific measurements of acute, multidimensional poverty and social factors. This enables trend analysis, integration of key social factors with financial analytics, and data tools to create and broaden access to sustainability-linked financing and investment.
- The Wise Responder Kits – packages that arm companies with valuable metrics and practical tools allowing them to deeply understand the wellbeing of their employees and other community stakeholders. The toolkits help guide and strengthen the client's human resources programmes and improve the targeting and impact of those programmes. This allows them to report the impact of their social investment in a standard metric.

Among Wise Responder's early corporate adopters are four Fortune Global 500 companies and one Fortune 500 company, including a global brewing and beverage company, a multinational oil and gas company, the world's largest fresh produce company, and two global financial services companies.

And, according to a new report by Citi GPS, the use of these metrics can unlock $1.6 trillion in annual incremental sustainability spending.

Wise Responder's science-backed products enable businesses and investors to see, measure and address poverty – a powerful way to make a difference.

"According to a new report by Citi GPS, the use of these metrics can unlock **$1.6 trillion** in annual incremental sustainability spending."

Quick Facts

44,270 employees surveyed

74 companies across **12** countries

Underlying OPHI research **won 2020 Queen's Anniversary Prize**

WISE RESPONDER

BibliU: Enabling equitable access to textbooks

By its own assertion, BibliU has an 'audacious vision for learning'.

Founded nearly ten years ago through OUI's startup incubator, BibliU aims to ensure all university and college students have affordable access to their class content, helping tackle issues around social mobility in higher education. To achieve this, the team has built partnerships with thousands of publishers and created a platform dedicated to making learning more equitable, effective, and efficient.

Quick Facts

More than **1.2 million** users since January 2016

221 publishers

More than **1.4 million** learning assets

Around **680,000** monthly study hours on average

BibliU's technology and platform focuses on three main offerings:

- Students benefit from software giving them access to textbooks and other course materials – essentially an unlimited ebook streaming service available from day one and included in their tuition fee.
- Using BibliU's tools, universities are able to automate workflows around course material selection, pricing and deployment.
- Teaching staff can access software helping them better understand how their students are performing over time.

"**BibliU** aims to ensure all university and college students have affordable access to their class content, helping tackle issues around social mobility in higher education."

Take the example of Jackson College – a public college in Michigan, USA. An impact report carried out on behalf of BibliU found that usage of its platform was correlated with better grades at Jackson. In fact, the more times Jackson students used BibliU, the better their grades: the average grade point average (GPA) of heavy users was one whole point higher than light users and higher than the college average.

The so-called 'BibliU cohort' – students who used BibliU and were first-time enrollees – had the highest retention rate at Jackson since autumn 2018.

OrganOx: Pioneering the future of organ transplantation

Ten years ago, in a world first, a donated human liver was 'kept alive' outside the body before being successfully transplanted into a patient. It was another milestone in the longstanding, groundbreaking collaboration between Oxford scientists Professor Constantin Coussios and Professor Peter Friend, and the spinout company they founded, OrganOx.

The technique, known as normothermic machine perfusion, maintains donated livers in a fully functioning state for up to 24 hours prior to transplantation. Compared with standard cold storage, this results in 50% fewer discarded livers and 20% more transplanted livers.

OrganOx technology gives surgeons time and data to decide whether a candidate liver is suitable for transplantation, as the higher storage temperature and increased functionality makes it easier to assess. There's also the flexibility: in a clinical trial, 84% of transplants took place during the day versus 65% with static cold storage.

These results are phenomenal for the hundreds of people waiting for a liver transplant in the UK alone. To date, OrganOx's *metra* product has supported more than 2,000 liver transplants worldwide, with last year's FDA regulatory approval enabling the technology to be applied to a huge unmet need in the United States.

The *metra* device is fully automated, transportable, and easy to set up and operate. It keeps donor livers perfused – supplied with oxygenated blood, medications and nutrients – at normal body temperature and in near-physiological condition. The 24-hour window of opportunity addresses the challenge of performing transplants in patients with substantial journey times.

Almost 30 years since Professors Coussios and Friend began working together, OrganOx has changed the game for organ transplantation worldwide.

"Compared with standard cold storage, this results in **50%** fewer discarded livers and **20%** more transplanted livers."

Quick Facts

>2,000 liver transplants worldwide

50% fewer discarded organs

20% more transplanted livers

>50 publications supporting OrganOx technology

Thank you to all the contributers to the inaugural 2023 OUI Impact Report.

BibliU

BRAINOMIX

Collegia

covatic

diffblue
AI for Code

Greater Change

Inkpath
Powering innovation in professional development

Lilium

mind
FOUNDRY

ORBIT

OrganOx
living organs for life

OxCarbon

OxEd
& Assessment

Oxford
NANOPORE
Technologies

RE•FEYN

seren

TAS
delta

The Global Health Research Accelerator
A Community Interest Company, Creating Equity in Health Research

ULTROMICS

vaccitech

WISE
RESPONDER

OXFORD UNIVERSITY
INNOVATION   UNIVERSITY OF
OXFORD
Consulting Services

OXFORD UNIVERSITY
INNOVATION   UNIVERSITY OF
OXFORD
Social Ventures

OXFORD UNIVERSITY
INNOVATION   UNIVERSITY OF
OXFORD
Clinical Outcomes

Please scan to view
the online version.